We are live on ! Find out more
ACHV icon

Achieve Life Sciences

77 hedge funds and large institutions have $115M invested in Achieve Life Sciences in 2025 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 24 increasing their positions, 12 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

548% more call options, than puts

Call options by funds: $1.39M | Put options by funds: $214K

140% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 10

136% more capital invested

Capital invested by funds: $48.9M → $115M (+$66.4M)

100% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 12

17% more funds holding

Funds holding: 6677 (+11)

13.24% more ownership

Funds ownership: 30.41%43.66% (+13%)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

Holders
77
Holders Change
+11
Holders Change %
+16.67%
% of All Funds
0.94%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
24
Increased
24
Reduced
12
Closed
10
Calls
$1.39M
Puts
$214K
Net Calls
+$1.17M
Net Calls Change
-$971K
Name Holding Trade Value Shares
Change
Change in
Stake
Franklin Resources
1
Franklin Resources
California
$21.7M +$18.9M +4,346,011 +18,747%
PBM
2
Propel Bio Management
California
$18.8M
Vanguard Group
3
Vanguard Group
Pennsylvania
$12.3M +$54.5K +12,510 +0.5%
Millennium Management
4
Millennium Management
New York
$6.75M +$4.89M +1,121,614 +472%
SAM
5
Simplify Asset Management
Nevada
$5.89M
Marshall Wace
6
Marshall Wace
United Kingdom
$5.07M +$1.07M +244,428 +32%
Two Sigma Investments
7
Two Sigma Investments
New York
$3.72M +$1.35M +309,552 +71%
NCM
8
Nantahala Capital Management
Connecticut
$3.22M
LPL Financial
9
LPL Financial
California
$3.15M +$1.32M +301,850 +91%
Geode Capital Management
10
Geode Capital Management
Massachusetts
$2.98M +$404K +92,634 +18%
Raymond James Financial
11
Raymond James Financial
Florida
$2.98M +$625K +143,307 +31%
Susquehanna International Group
12
Susquehanna International Group
Pennsylvania
$2.47M +$567K +129,987 +35%
KCA
13
KVP Capital Advisors
California
$2.3M +$2.02M +462,355 New
Goldman Sachs
14
Goldman Sachs
New York
$2.24M +$990K +227,095 +101%
BlackRock
15
BlackRock
New York
$2.08M +$122K +27,893 +7%
Jane Street
16
Jane Street
New York
$1.9M +$1.67M +382,211 New
Pathstone Holdings
17
Pathstone Holdings
New Jersey
$1.86M -$372K -85,333 -17%
UBS Group
18
UBS Group
Switzerland
$1.42M +$898K +206,087 +260%
SC
19
Shay Capital
New York
$1.17M -$238K -54,608 -19%
State Street
20
State Street
Massachusetts
$1.16M +$60.5K +13,873 +6%
Northern Trust
21
Northern Trust
Illinois
$1.14M +$45.5K +10,434 +5%
6CM
22
683 Capital Management
New York
$1.07M +$937K +214,897 New
Two Sigma Advisers
23
Two Sigma Advisers
New York
$1.04M +$434K +99,600 +90%
BNP Paribas Financial Markets
24
BNP Paribas Financial Markets
France
$835K +$731K +167,635 +54,076%
Squarepoint
25
Squarepoint
New York
$818K -$909K -208,474 -56%

ACHV Hedge Fund Activity: Q4 2025 in Review

77 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in Achieve Life Sciences (ACHV) for Q4 2025, worth a combined $115M — up 136% from $48.9M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new ACHV positions and 10 closed out — a net gain of 14 holders — while 24 added to existing stakes and 12 trimmed.

The largest buyer was Franklin Resources, adding an estimated $18.9M. The largest seller was Clearline Capital, exiting entirely with an estimated $1.42M sold.

  • 77 institutional investors held Achieve Life Sciences (ACHV) as of Q4 2025, up from 66 in Q3 2025.
  • Funds reported $115M of Achieve Life Sciences stock for Q4 2025, up 136% quarter-over-quarter.
  • 24 funds opened new Achieve Life Sciences positions in Q4 2025 and 10 closed out, a net change of +14 holders.
  • The largest Achieve Life Sciences buyer in Q4 2025 was Franklin Resources, an estimated $18.9M added.
  • The largest Achieve Life Sciences seller in Q4 2025 was Clearline Capital, an estimated $1.42M sold.

Based on aggregated 13F filings for Q4 2025.